ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02237235
Recruitment Status : Completed
First Posted : September 11, 2014
Last Update Posted : September 5, 2017
Sponsor:
Collaborators:
Neurocentria, Inc.
Brain & Behavior Research Foundation
Information provided by (Responsible Party):
Herbert Meltzer, Northwestern University

Brief Summary:
The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with stable levels of positive symptoms. Secondary end points will include changes in positive and negative symptoms. One dose of MMFS-202-302 will be studied and compared with placebo as adjunctive treatment to atypical antipsychotic drug treatment.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorder Drug: MMFS-202-302 Drug: Placebo Phase 2

Detailed Description:

One of the symptoms of schizophrenia is a problem with specific domains of cognition, even when the positive symptoms have been treated. The primary goal of this study is to determine the effectiveness of 9 weeks of supplementation with MMFS-202-302 as augmentation of atypical antipsychotic medication, to improve a critical specific domain of cognitive function, i.e., working memory, in patients with schizophrenia or schizoaffective disorder. To support this primary goal, global function will be assessed with the Clinical Global Impression assessment of change.

The investigators will also examine the effect of MMFS-202-302 on other domains of cognition (e.g. attention, executive function, declarative memory, etc.); negative symptoms of schizophrenia; positive symptoms of schizophrenia; MRI measures of brain structure, resting state functional connectivity, and function during evaluation of emotional/unemotional and rewarding/aversive images and anticipation and receipt of reward and punishment, and working memory; and EEG measurement of network interactivity during learning and memory recollection.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
Study Start Date : August 2014
Actual Primary Completion Date : August 2017
Actual Study Completion Date : August 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: MMFS-202 -302

MMFS-202: evening dose

MMFS-302: morning dose

Drug: MMFS-202-302

Active ingredient: L-Threonic acid Magnesium salt.

1 g (2 pills) by mouth once daily in the evening for 9 weeks

Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt

1 g (2 pills) by mouth once daily in the morning for 9 weeks


Placebo Comparator: Placebo
Placebo
Drug: Placebo
Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.




Primary Outcome Measures :
  1. Matrics Consensus Cognitive Battery (MCCB) [ Time Frame: Baseline to Day 63 ]
    Change from Baseline in MATRICS Consensus Cognitive Battery (MCCB) working memory domain.


Secondary Outcome Measures :
  1. Overall clinical global impression of severity improvement measured by the Clinical Global Impressions Scale assessment of change (CGI-C) [ Time Frame: Day 63 ]
    To support the primary endpoint of working memory, the CGI-C will demonstrate clinically relevant improvement of global function.


Other Outcome Measures:
  1. Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) total score [ Time Frame: Baseline to Day 63 ]
  2. Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) speed of processing domain subscale score [ Time Frame: Baseline to Day 63 ]
  3. Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) attention/vigilance domain subscale score [ Time Frame: Baseline to Day 63 ]
  4. Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) verbal learning domain subscale score [ Time Frame: Baseline to Days 42 and 63 ]
  5. Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) visual learning domain subscale score [ Time Frame: Baseline to Day 63 ]
  6. Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) reasoning and problem solving domain subscale score [ Time Frame: Baseline to Day 63 ]
  7. Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) social cognition domain subscale score [ Time Frame: Baseline to Day 63 ]
  8. Change from Baseline in cognition measured by the FAS Phonemic Fluency test [ Time Frame: Baseline to Day 63 ]
  9. Change from Baseline in cognition measured by the Brown-Peterson's Auditory Consonant Trigrams test [ Time Frame: Baseline through Day 63 ]
  10. Change from Baseline in cognitive outcomes among subgroups of subjects with deficits in the respective cognitive domain [ Time Frame: Baseline to Day 63 ]
    Cognitive outcomes will be reanalyzed, restricted to the subgroup of subjects whose baseline score is at or below median for healthy age-matched norms (T-score of 50 or below) for the respective cognitive outcome of interest. Analogous analyses will be carried out using more conservative cutoffs of one half and one standard deviation below median (T-score of 45 and 40 or below).

  11. Change from Baseline in cognition measured by the Wisconsin Card Sorting Test [ Time Frame: Baseline to Day 63 ]
  12. Change from Baseline in working memory composite score [ Time Frame: Baseline to Day 63 ]
  13. Change from Baseline in Negative symptoms measured by the Brief Negative Symptom Scale (BNSS) [ Time Frame: Baseline to Day 63 ]
  14. Change from Baseline in Negative symptoms measured by the Positive and Negative Syndrome Scale (PANSS) negative symptom subscale [ Time Frame: Baseline to Day 63 ]
  15. Change from Baseline in Negative symptoms measured by the Calgary Depression Scale for Schizophrenia (CDSS) [ Time Frame: Baseline to Day 63 ]
  16. Change from Baseline in Positive symptoms measured by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale [ Time Frame: Baseline to Days 42 and 63 ]
  17. Overall clinical global impression of severity improvement measured by the change from Baseline of Clinical Global Impressions Scale assessment of severity (CGI-S) [ Time Frame: Baseline to Day 63 ]
  18. Change from Baseline in brain structure and function [ Time Frame: Baseline to Day 63 ]
    Magnetic Resonance Imaging (MRI) measures of brain structure; resting state functional connectivity; and activation patterns during performance of a working memory paradigm, and of brain reward networks during affective/neutral image appraisal and reward/loss anticipation and outcome (regions of interest: OMPFC, ACC, NAc, VTA).

  19. Change from Baseline neural activity and connectivity during learning and memory recollection measured by EEG [ Time Frame: Baseline to Day 63 ]
  20. Change from Baseline of red blood cell magnesium levels in relation to efficacy outcome measures [ Time Frame: Baseline to Day 63 ]
    Red blood cell magnesium level will be evaluated as a putative surrogate biomarker of target engagement, as a predictor of efficacy.

  21. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Baseline through Day 63, or Early Termination ]
    To evaluate safety and tolerability of MMFS-202-302 in patients with schizophrenia or schizoaffective disorder maintained on a stable dose of an atypical antipsychotic, each grade of adverse event will be evaluated individually, as well as the total number of all grades of adverse events

  22. Responder analyses [ Time Frame: Baseline to Day 63 ]
    The number of subjects achieving a cutoff of improving at least one half of a standard deviation (T-score change > 5) on the working memory subscale of the MCCB will be compared between the MMFS-202-302 and Placebo groups. Analogous responder analyses will be carried out for other efficacy outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients must be capable of giving written informed consent.
  2. Male or female subjects of any race; between 18 to 60 years of age, inclusive.
  3. No hospitalization other than for evaluation in the past four months
  4. Resides in a stable living situation, according to the investigator's judgment.
  5. Diagnosis of schizophrenia or schizoaffective disorder of at least one-year duration, as established by the SCID-I, and verified with medical records and/or confirmation of diagnosis by treating clinician. The illness is in a nonacute phase as determined by the subject's primary treating clinician
  6. Current psychotropic drug treatment consists of monotherapy with an atypical antipsychotic drug.
  7. No more than a mild level of EPS as determined by the Simpson Angus Scale (SAS) total score: ≤ 6
  8. Not taking anticholinergic medication for EPS
  9. No evidence of tardive dykinesia
  10. Subjects healthy enough to complete a 9-week clinical trial
  11. Women of childbearing potential must have a negative pregnancy test at screening and baseline, and agree to use adequate protection (i.e. double barrier method) for birth control.
  12. Able to complete cognition assessments in English
  13. General intellectual abilities falling broadly within the average estimated IQ > 80, as measured by the Wide Range Achievement Test - 4th Edition (WRAT-IV).

Exclusion Criteria:

  1. Failure to perform screening or baseline examinations
  2. Hospitalization within 8 weeks before screening, or change of antipsychotic medication or dose within 2 months prior to screening
  3. Subjects who have participated in another clinical trial with an experimental medication within the past 2 months.
  4. Patient has had cognitive battery similar to those used in this study within the last 12 months
  5. Subjects with other DSM-V Axis I or Axis II primary diagnoses
  6. Diagnosis of alcohol or substance abuse or dependence within the past 3 months,
  7. Significant suicide risk as determined by the Columbia Suicide Severity Rating Scale (C-SSRS)
  8. Subjects who plan to begin a new course of cognitive remediation therapy, or have been receiving cognitive remediation therapy for less than one year. .
  9. History of myocardial infarction, unstable angina, uncontrolled hypotension or hypertension within 3 months before screening.
  10. Clinically significant abnormality on screening ECG
  11. Alanine transaminase (ALT) or aspartate transaminase (AST) > 2.5 times the upper limit of normal (ULN)
  12. History of stroke, brain tumor, head trauma with loss of consciousness, or other clinically significant neurological condition within 12 months before screening
  13. Subjects with other uncontrolled medical conditions, in the opinion of the investigator
  14. Polypharmacy with two or more antipsychotic drugs or mood stabilizers
  15. Use of benzodiazepines
  16. Individuals with kidney dysfunction will not be enrolled, as dysfunctional kidneys may have difficulty clearing the magnesium from the body
  17. Individuals who are currently taking magnesium supplements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02237235


Locations
United States, Illinois
Northwestern University Psychiatric Clinical Research Program
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Neurocentria, Inc.
Brain & Behavior Research Foundation
Investigators
Principal Investigator: Herbert Y Meltzer, MD Northwestern University

Responsible Party: Herbert Meltzer, Professor of Psychiatry, Physiology and Pharmacology, Northwestern University
ClinicalTrials.gov Identifier: NCT02237235     History of Changes
Other Study ID Numbers: STU00098144
First Posted: September 11, 2014    Key Record Dates
Last Update Posted: September 5, 2017
Last Verified: August 2017

Keywords provided by Herbert Meltzer, Northwestern University:
Schizophrenia
Schizoaffective disorder
Cognition
Magnesium
Imaging
Negative symptoms

Additional relevant MeSH terms:
Schizophrenia
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders